Emerging therapies that target epigenetic modifications, including DNA methylation, histone modifications, and RNA regulation. They include several classes according to their genetic target e.g. Inhibitors of DNA Methyltransferases (DNMTs), Histone Deacetylase (HDAC) Inhibitors, and Protein Arginine Methyltransferase (PRMT) Inhibitors. They offer exciting prospects for improving lymphoma treatment.
Published in Chapter:
Mature T/NK Proliferations/Lymphomas and HL: Diagnostic Approach
Copyright: © 2024
|Pages: 32
DOI: 10.4018/978-1-6684-5818-1.ch013
Abstract
“T and NK-cell lymphoid proliferations and lymphomas” comprise nine groups with distinct cell origins, differentiation states, clinical features, localization, and cytomorphology. Most correspond to specific T or NK lineage. Still, few have a hybrid or indeterminate phenotype, including extranodal NK and T-cell lymphoma, EBV+ nodal T/NK-cell lymphoma, chronic active EBV disease, and severe mosquito bite allergy. The distinction between T- and NK cells is sometimes unclear. The main categories are Mature T-cell and NK-cell leukemias, Primary cutaneous T-cell lymphoid proliferations and lymphomas (CTCL), Intestinal T- and NK-cell lymphoid proliferations and lymphomas, Nodal T-Follicular Helper Cell Lymphomas, Peripheral T-cell lymphomas (PTCLs), EBV-related mature T-cell and NK-cell neoplasms, and Extranodal NK/T-cell lymphoma (ENKTL). HL comprises classical HL (cHL) and nodular lymphocyte predominant HL (NLPHL) subtypes.